Real-World Evidence of Clinical Outcomes in Patients With Assumed Classic Congenital Adrenal Hyperplasia in the United States

por Farrar, Mallory, Farber, Robert, Sen, Ginny P, Yonan, Charles, Chan, Jean Lin
Publicado 2021

MON-183 Adrenal Androgen Control and Steroidal Side Effects in Adolescents and Adults with Congenital Adrenal Hyperplasia Treated with Glucocorticoids

por Falhammar, Henrik, Farber, Robert, Chan, Jean L, Farrar, Mallory, Yonan, Chuck, Kuranz, Seth, Auchus, Richard J
Publicado 2020

Noninvasive predictors of clinically significant portal hypertension in NASH cirrhosis: Validation of ANTICIPATE models and development of a lab‐based model

por Rabiee, Anahita, Deng, Yanhong, Ciarleglio, Maria, Chan, Jean L., Pons, Monica, Genesca, Joan, Garcia‐Tsao, Guadalupe
Publicado 2022

Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non‐alcoholic fatty liver disease

por Shiffman, Mitchell, Freilich, Bradley, Vuppalanchi, Raj, Watt, Kymberly, Chan, Jean L., Spada, Al, Hagerty, David T., Schiff, Eugene
Publicado 2018

Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus

por Barrat, Franck J., Meeker, Thea, Gregorio, Josh, Chan, Jean H., Uematsu, Satoshi, Akira, Shizuo, Chang, Bonnie, Duramad, Omar, Coffman, Robert L.
Publicado 2005

Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation

por Guiducci, Cristiana, Ott, Gary, Chan, Jean H., Damon, Emily, Calacsan, Carlo, Matray, Tracy, Lee, Kyung-Dall, Coffman, Robert L., Barrat, Franck J.
Publicado 2006

OR18-4 Crinecerfont (NBI-74788), a Novel CRF1 Receptor Antagonist, Lowers Adrenal Androgens and Precursors in Adolescents with Classic Congenital Adrenal Hyperplasia

por Auchus, Richard, Chan, Jean, Farber, Robert, Fechner, Patricia, Giri, Nagdeep, Nokoff, Natalie, Roberts, Eiry, Sarafoglou, Kyriakie, Sturgeon, Julia, Vogiatzi, Maria, Newfield, Ron
Publicado 2022

Changes in Adrenal and Gonadal Androgens After 14-Day Treatment With CRF1 Receptor Antagonist, Crinecerfont (NBI-74788), in Men With Classic 21-Hydroxylase Deficiency

por He, Xin, Sarafoglou, Kyriakie, Fechner, Patricia Y, Vogiatzi, Maria George, Imel, Erik Allen, Davis, Shanlee Marie, Sturgeon, Julia, Chan, Jean Lin, Farber, Robert, Auchus, Richard Joseph
Publicado 2021

Growth-Related Characteristics of Patients <18 Years of Age with Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency (21OHD): Real World Evidence from the I-CAH Registr...

por Farrar, Mallory, Ali, Salma Rashid, Bryce, Jillian, Baronio, Federico, Claahsen-van der Grinten, Hedi L, Bonfig, Walter, Yonan, Charles, Farber, Robert, Chan, Jean Lin, Ahmed, S Faisal
Publicado 2021

Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia

por Auchus, Richard J, Sarafoglou, Kyriakie, Fechner, Patricia Y, Vogiatzi, Maria G, Imel, Erik A, Davis, Shanlee M, Giri, Nagdeep, Sturgeon, Julia, Roberts, Eiry, Chan, Jean L, Farber, Robert H
Publicado 2021

Crinecerfont, a CRF(1) Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal Hyperplasia

por Newfield, Ron S, Sarafoglou, Kyriakie, Fechner, Patricia Y, Nokoff, Natalie J, Auchus, Richard J, Vogiatzi, Maria G, Jeha, George S, Giri, Nagdeep, Roberts, Eiry, Sturgeon, Julia, Chan, Jean L, Farber, Robert H
Publicado 2023

Emricasan (IDN‐6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension

por Garcia‐Tsao, Guadalupe, Fuchs, Michael, Shiffman, Mitchell, Borg, Brian B., Pyrsopoulos, Nikolaos, Shetty, Kirti, Gallegos‐Orozco, Juan F., Reddy, K. Rajender, Feyssa, Eyob, Chan, Jean L., Yamashita, Mason, Robinson, James M., Spada, Alfred P., Hagerty, David T., Bosch, Jaime
Publicado 2018